Inno Medicine Secures Nearly $110M+ to Advance Targeted Nanomedicines for Atherosclerosis and Glioma
Beijing-based Inno Medicine has raised nearly RMB 800 million (roughly $110 million-plus) in a Series D financing, giving the Chinese nanomedicine developer substantial new capital as its two flagship programs move deeper into global clinical…
Unike Biopharma Raises Tens of Millions of RMB to Advance Long-Acting Protein and Peptide Drug Platform
Hangzhou-based Unike Biopharma has completed an angel financing round worth tens of millions of RMB, giving the young biotech fresh capital to advance a broad pipeline of long-acting protein and peptide therapeutics built around its proprietary ZT…
ALLYRNA Raises Over RMB 100 Million to Advance RNA Epigenetics-Based Cancer Drug Pipeline
Shanghai-based ALLYRNA has raised more than RMB 100 million in Seed+ financing to advance a new generation of small-molecule cancer therapies derived from RNA epigenetics, including potential radiotherapy and immunotherapy sensitizers for…
AusperBio Raises $120 Million Series C to Advance AHB-137 Toward Hepatitis B Functional Cure and Commercialization
AusperBio has raised $120 million in Series C financing to advance its lead chronic hepatitis B therapy AHB-137 through Phase III development and prepare for potential commercialization, while expanding a next-generation pipeline of siRNA and combination…